Nonresectional regional therapies for metastatic colorectal cancer to the liver

Schlick, Cary Jo R.; Merkow, Ryan P.; Bentrem, David J.

doi:10.1002/jso.25423

Cited by 8 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer (CRC), a digestive system tumor, is currently the third most common malignant cancer worldwide 1 . Despite the improvements in diagnosis and therapeutic methods, the high risk of liver metastasis and poor prognosis of patients with advanced colorectal cancer remain to be addressed 2 . Currently, surgery combined with chemotherapy and radiotherapy is still served as the predominant treatment for colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%

Integrated proteomics and metabolomics reveals the comprehensive characterization of antitumor mechanism underlying Shikonin on colon cancer patient-derived xenograft model

Yang

Gao

et al. 2020

Sci Rep

View full text Add to dashboard Cite

colorectal cancer (cRc) is a common malignancy occurring in the digestive system. Despite progress in surgery and therapy options, cRc is still a considerable cause of cancer mortality worldwide. in this study, a colon cancer patient-derived xenograft model was established to evaluate the antitumor activity of Shikonin. The protective effect underlying Shikonin was determined through assessing serum levels of liver enzymes (ALt, ASt) and kidney functions (Bun, Scr) in pDX mice. proteomics and metabolomics profiles were integrated to provide a systematic perspective in dynamic changes of proteins and global endogenous metabolites as well as their perturbed pathways. A total of 456 differently expressed proteins (DEPs), 32 differently expressed metabolites (DEMs) in tumor tissue, and 20 DEMs in mice serum were identified. The perturbation of arginine biosynthesis, purine metabolism, and biosynthesis of amino acids may mainly account for therapeutic mechanism of Shikonin. Furthermore, the expression of mRNAs participating in arginine biosynthesis (CPS1, OTC, Arg1) and do novo purine synthesis (GART, PAICS, ATIC) were validated through RT-qPCR. Our study provides new insights into the drug therapeutic strategies and a better understanding of antitumor mechanisms that might be valuable for further studies on Shikonin in the clinical treatment of colorectal cancer. Colorectal cancer (CRC), a digestive system tumor, is currently the third most common malignant cancer worldwide 1. Despite the improvements in diagnosis and therapeutic methods, the high risk of liver metastasis and poor prognosis of patients with advanced colorectal cancer remain to be addressed 2. Currently, surgery combined with chemotherapy and radiotherapy is still served as the predominant treatment for colorectal cancer. However, their side effects are considerable. Hence, the development of natural products has become a priority for the therapy of colorectal cancer. Shikonin (SHK), a naphthoquinone pigment isolated from the root of Lithospermum erythrorhizon (Sieb. et Zucc, Boraginaceae) (Fig. 1), has been reported to be highly effective against a variety of cancer types during the past decades 3. Shikonin was demonstrated to suppress proliferation and induce cell cycle arrest in human colon cancer through inhibiting hypoxia-inducible factor-1 alpha signaling both in vitro and vivo 4. Shikonin induced

show abstract

Section: Introductionmentioning

confidence: 99%

Integrated proteomics and metabolomics reveals the comprehensive characterization of antitumor mechanism underlying Shikonin on colon cancer patient-derived xenograft model

Yang

Gao

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Although surgical resection is considered the favored approach to CRLM, based on current literature, there is poor evidence that nonresectional therapy is inferior to surgical resection. 23…”

Section: Ablative Therapies For Metastatic Colorectal Cancer To the L...mentioning

confidence: 99%

Surgical and Interventional Management of Liver Metastasis

Itenberg

Lozano

2022

Clin Colon Rectal Surg

View full text Add to dashboard Cite

Colorectal cancer is one of the most common cancers diagnosed worldwide. While the incidence of colorectal cancer has been declining since the adoption of screening colonoscopy, the findings of liver metastasis are still found in up to 25% of patients at diagnosis. The management of liver metastasis has evolved over the past two to three decades, and survival rates have improved secondary to improved systemic therapy, surgical options, and local therapies. In this article, we aim to review the available surgical and ablative options for management of colorectal liver metastasis, as well as appropriate imaging and patient selection.

show abstract

“…Currently, surgical resection combined with chemotherapy and radiotherapy is still served as the predominant treatment for early-and mid-stage patients with localized colon cancer. However, their side effects are considerable, and the poor prognosis is valued to be addressed (Schlick et al, 2019). Hence, the development of natural products has become a priority for the therapy of colorectal cancer.…”

Section: Introductionmentioning

confidence: 99%